Alphyn
Manufacturing · Maryland, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3724a Thomas Point Rd, Annapolis, Maryla...Phone Number
(410) 690-8687Website
www.alphynbiologics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Alphyn
Alphyn Biologics is a life sciences company focused on developing breakthrough therapies for challenging skin diseases, including atopic dermatitis and epidermolysis bullosa. The company utilizes its proprietary Zabalafin Platform to create Multi-Target Therapeutics (MTT) that aim to provide safe, effective, and comprehensive treatments. Their lead product, zabalafin hydrogel, is a steroid-free topical treatment for mild-to-moderate atopic dermatitis, designed to improve patient quality of life with minimal side effects. Alphyn Biologics targets individuals suffering from severe and common skin diseases, with a mission to enhance the lives of millions globally.Explore more
Alphyn Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alphyn your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Alphyn recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Alphyn
Click to see if Alphyn had a recent Job posting/layoffs
Product Launch: Get notified when Alphyn launches new products
Funding: Get notified immidiatlly once Alphyn has new funding data
Check if Alphyn has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Alphyn is spiking on competitors!
Alphyn, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Alphyn as Masked Content
Find more new buyers
Compare Similar Companies to Alphyn
Compare insights from companies similar to Alphyn, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alphyn is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alphyn is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alphyn.
Alphyn financials insights
Gather financial insights about Alphyn, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$3.3M
2025
Series B
$25M
Alphyn Tech Stack
A closer look at the technologies used by Alphyn
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Funding
Funding
Project
Intellectual Property, Legal Affairs, Pharmaceuticals, Healthcare Technology
Funding
Alphyn News & Media
Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis
Multi-target therapeutic aims to treat all key and interconnected problems of atopic dermatitis ANNAPOLIS, Md., March 11, 2026 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing the first Multi-Target Therapeutics® drug platform, announced today that it has completed...First Patients Dosed in Alphyn Biologics' Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum
New program expands pipeline derived from Alphyn's proprietary multi-target drug platform ANNAPOLIS, Md., Feb. 18, 2026 /PRNewswire/ -- Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, today announced dosing of the first...Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ -- Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,...Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic
Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office (USPTO) has...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alphyn
Sign Up For FreeTo access detailed company insights
Alphyn Biologics is a life sciences company focused on developing breakthrough therapies for challenging skin diseases, including atopic dermatitis and epidermolysis bullosa. The company utilizes its proprietary Zabalafin Platform to create Multi-Target Therapeutics (MTT) that aim to provide safe, effective, and comprehensive treatments. Their lead... Read More
